Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy of repeated adenoviral suicide gene therapy in a localized murinetumor model
Autore:
Lambright, ES; Force, SD; Lanuti, ME; Wasfi, DS; Amin, KM; Albelda, SM; Kaiser, LR;
Indirizzi:
Univ Penn, Med Ctr, Thorac Oncol Res Lab, Philadelphia, PA 19104 USA Univ Penn Philadelphia PA USA 19104 l Res Lab, Philadelphia, PA 19104 USA
Titolo Testata:
ANNALS OF THORACIC SURGERY
fascicolo: 6, volume: 70, anno: 2000,
pagine: 1865 - 1870
SICI:
0003-4975(200012)70:6<1865:EORASG>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
THYMIDINE KINASE GENE; I CLINICAL-TRIAL; CELL LUNG-CANCER; IMMUNE-RESPONSES; TRANSGENE EXPRESSION; MOUSE-LIVER; TRANSIENT IMMUNOSUPPRESSION; GANCICLOVIR THERAPY; MESOTHELIOMA; VECTORS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Kaiser, LR Hosp Univ Penn, 6 Silverstein Pavil,3400 Spruce St, Philadelphia, PA 19104USA Hosp Univ Penn 6 Silverstein Pavil,3400 Spruce St Philadelphia PA USA 19104
Citazione:
E.S. Lambright et al., "Efficacy of repeated adenoviral suicide gene therapy in a localized murinetumor model", ANN THORAC, 70(6), 2000, pp. 1865-1870

Abstract

Background. Gene therapy using adenovirus to deliver herpes simplex virus thymidine kinase (Ad.HSVtk) followed by the administration of the prodrug ganciclovir has been an effective anticancer therapy in models of localized tumor (including malignant mesothelioma) and is currently being evaluated in clinical trials. To optimize this approach, we studied the effects of repeated injections of Ad.HSVtk in an animal model of localized tumor in both naive and immunized mice. Methods. Immunocompetent animals with established abdominal tumor were treated with either one or three (given weekly) intraperitoneal injections of Ad.HSVtk (10(9) plaque-forming units) followed by daily ganciclovir and monitored for survival. Survival studies were also performed in mice previously immunized with adenovirus. Results. Animals treated with multiple courses of Ad.HSVtk showed significantly improved survival versus singly injected animals and control animals with some long-term survivors in the multiple injected group. Preexisting neutralizing immunity did not diminish this survival advantage. Conclusions. Multiple treatments using an adenoviral vector to deliver HSVtk significantly improves survival in a murine intraperitoneal tumor model. The presence of preexisting neutralizing antibodies does not blunt this effect. Repeat Ad.HSVtk is a feasible approach and may be a useful strategy in human cancer gene therapy. (Ann Thorac Surg 2000;70:1865-71) (C) 2000 by The Society of Thoracic Surgeons.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/09/20 alle ore 22:00:39